Barclays Maintains Overweight on Sotera Health, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on Sotera Health (NASDAQ:SHC) and increased the price target from $15 to $17.
January 25, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on Sotera Health and raises the price target from $15 to $17.
The increase in price target by Barclays reflects a positive outlook on Sotera Health's stock, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100